Autopsy report · NCT00876915
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Cause of deathSlow enrollment, also funding or business
“slow enrollment and lack of continuing funds”
Life of this trial
- Registered 3 months before it started.
- Ran for about 5 years 5 months before it stopped.
- 218 participants enrolled.
- Results were posted on the registry 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- University of Rochester
- Sponsor type
- University, hospital or other
- Conditions
- Venous Thromboembolism; Pulmonary Embolism
- Interventions
- dalteparin injection
- Participants
- 218
- Sites
- 7
- Countries
- Canada, United States
Trials that died the same way
- Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity
“Slow enrollment and financial issues” - Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
“Slow enrollment and financial constraints.” - Study to Analyze the Effects of EBI OsteoGen™ on the Surgical Reconstruction of Tibia Non-unions
“Slow enrollment, lack of follow up” - EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus
“Slow enrollment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.